This content is protected against AI scraping.
Rep. Andy Barr (R-KY) recently introduced a new bipartisan hemp bill alongside co-sponsor Rep. Angie Craig (D-MN), initially claiming in a press release that the proposal had full White House backing. However, the Trump administration has hesitated to explicitly endorse the 60-page draft. While President Trump has publicly called on Congress to protect CBD access and avert the federal ban scheduled for November, White House officials declined to confirm direct support for this specific bill, and the phrase claiming White House backing was later removed from the press release on Representative Barr’s website.
The primary sticking point appears to be inhalable hemp products. Sources familiar with the negotiations indicate that the White House opposes keeping smokeable or inhalable hemp legal, favoring a narrower focus on oral CBD and therapeutic treatments instead. Although President Trump previously expressed support for earlier regulatory frameworks and introduced Medicare initiatives for CBD access, his administration has refrained from giving Representative Barr’s current draft an official endorsement.
With the November deadline approaching, attention is turning to the Senate, where a modified version of the bill is expected from Senators Tim Sheehy (R-MT) and Amy Klobuchar (D-MN). The upcoming Senate draft may adjust the provisions regarding inhalable products to address the administration’s concerns and secure executive support. For now, the hemp industry continues to navigate mixed signals from Washington as lawmakers work toward a legislative compromise that can pass both chambers.
This is a summary.
Please read the original article: GOP Lawmaker Claims White House Backs His Hemp Bill, But Administration Has Problems With Inhalable Product Provisions, Sources Say
Original article written by Tom Angell. Published on July 22, 2026 by Marijuana Moment.







